Navigation Links
Stanford-StartX Fund-Backed Nirmidas Biotech Raises $2 Million for Diagnostic Research Tools

Palo Alto, CA (PRWEB) August 18, 2014

Nirmidas Biotech, Inc., a diagnostic research technology company, is announcing that it has raised $2 million in seed round funding to commercialize its fluorescence enhancing plasmonic gold technology, called “pGOLD.” The technology platform, which significantly boosts the ability to detect disease biomarkers, is based on nearly a decade of research at Stanford University and is showing great promise as a diagnostic research tool in the life science and pharmaceutical fields. Nirmidas investors include a prominent VC firm, a life science angel investor, and the Stanford-StartX Fund.

With pGOLD technology, afflictions such as cancer, auto-immune disorders, cardiovascular disease, and diabetes can be detected at earlier stages and with better accuracy by creating non-invasive, point-of-care testing. Early detection could significantly change the nature and cost of patient care.

Dr. Hongjie Dai, the scientific co-founder of Nirmidas Biotech and Chaired Professor of Chemistry at Stanford, has published several academic papers about the technology. Dr. Dai’s passion for pGOLD’s potential to improve early detection outcomes and patient care led him develop market opportunities for his discoveries.

“Fluorescence is broadly used in diagnostic testing and biological research. Our signal enhancing technology simply makes it easier to see and detect various debilitating medical issues and diseases at the earliest stage possible. We believe it can be a real life saver,” said Dr. Hongjie Dai, Co-founder of Nirmidas Biotech.

The core of the pGOLD technology platform consists of an ultra-thin, film-like fluorescence enhancing plasmonic gold coating and its proprietary application technique. pGOLD Chips and pGOLD Beads came to market in mid-March. The products offer near-infrared fluorescence signal enhancement over 100-fold. This enables increased sensitivity, higher signal to noise ratio, high degree of multiplexing, and improved specificity, potentially leading to more rapid and accurate early-stage disease diagnoses incorporated into wearable healthcare, a market that is estimated to eventually be in excess of $2 billion dollars.

“The early adopters have been very satisfied with how pGOLD Chips and pGOLD Beads address their immediate research needs. We’ve surpassed their expectations and inspired them to envision the boundless product extensions and applications,” said Dr. Meijie Tang, CEO and Co-founder of Nirmidas Biotech.

As featured in prominent publications such as Nature Medicine and Nature Communications, pGOLD Chips and pGOLD Beads are now being commercialized by Nirmidas for the research community, the pharmaceutical community and other life science companies, as well as for in vitro diagnostic companies.

About Nirmidas Biotech, Inc.

Nirmidas Biotech, Inc., provides solutions for bio-analytical and diagnostic researchers using plasmonic gold (pGOLD) technology that vastly enhances near-infrared fluorescence signal, optimized over nearly a decade of research. Stanford Chaired Professor Dr. Hongjie Dai, a renowned nanotechnology expert, and Dr. Meijie Tang founded the Palo Alto-based company in 2013 with a vision for crafting innovative solutions to improve human life quality by developing breakthrough products at the intersection of life science research, in vitro diagnosis, and digital healthcare. Nirmidas is a resident at Janssen Labs @QB3 as well as StartX Med, a Stanford-affiliated nonprofit technology accelerator program. For more information, please visit:

About StartX

StartX is a 501(c)(3) Stanford-affiliated nonprofit in Silicon Valley that runs one of the world’s top startup accelerator programs. Our mission is to advance the development of the best entrepreneurs through experiential education and collective intelligence. Since launching in 2010, we have supported more than 160 companies and 370 entrepreneurs across a wide spectrum of industries. StartX and StartX Med, dedicated to medical and biotechnology, provides founders with access to a powerful network of entrepreneurs, investors, mentors, and industry partners, along with office space and a variety of other resources. We are supported by Stanford University, Stanford Hospital & Clinics, Kauffman Foundation, Microsoft, Steelcase, Intuit, Blackstone Charitable Foundation, Greylock Partners, Draper Fisher Jurvetson, Sequoia Capital, Merck, Genentech, Johnson & Johnson and many others. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
2. Pharma and Biotech Consulting Firm Announces New Website, Expanded Services
3. Registration Opens for the 2013 BioTechniques Virtual Symposium—Exploring the Modern Lab
4. Second annual Brain Tumor Biotech Summit 2013 at Weill Cornell
5. Biotechnology Market Is Expected to Reach USD 414.5 billion in 2017 : Transparency Market Research
6. New Biotechnology Report: Regenerative Medicine Markets
7. Cattle flatulence doesnt stink with biotechnology
8. Ganeden Biotech Hits IFT Annual Conference
9. Nanobiotechnology Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research
10. U.S. Environmental Biotechnology Product Market: 2018 Forecasts and Analysis Research Report Now Available at
11. Ganeden Biotech® Invests in Consumer Education with Its New GanedenBC30® Website
Post Your Comments:
(Date:11/25/2015)... ... ... The holiday season is jam-packed with family dinners, parties ... is of the utmost importance. Whether you are cooking at home for the ... try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the ... loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and ... hair, without the need for surgery, prescription pills, or topical foams. , “Capillus272™ ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology: